PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026BMJ Innovations0 citations

Evaluating Heartfelt’s predictive utility in heart failure: insights from the FOOT multicentre trial

View Full Paper
MDMatthew DewhurstKHKaren HannIMIain Matthews

Key Result

The Heartfelt remote monitoring device predicted heart failure decompensation with a 13-day lead time, providing more consistent and frequent data than traditional weighing methods.

Key Points

  • The study evaluates the Heartfelt device's effectiveness in predicting heart failure events through remote monitoring.
  • Conducted as an observational study across five UK NHS trusts.
  • Enrolled 31 patients, with 26 actively monitored for heart failure events.
  • Assessed predictive accuracy and data collection frequency of the Heartfelt device versus traditional methods.
  • Heartfelt device predicted heart failure decompensation with a lead time of 13 days.
  • Provided more consistent and frequent data collection compared to traditional weighing.
  • Six heart failure events were observed among monitored patients.

Structured PICO

Does the Heartfelt device improve the prediction of heart failure decompensation compared to traditional weighing in patients with heart failure?

P
Population
Patients with heart failure
I
Intervention
Heartfelt device for remote, autonomous monitoring of peripheral oedema
C
Comparator
Traditional weighing (standard care)
O
Outcome
Predictive accuracy, data collection frequency, consistency versus traditional weighing, lead time for intervention and event prediction sensitivity

The Heartfelt device provides continuous remote monitoring of peripheral edema, potentially allowing for earlier detection of heart failure decompensation with a 13-day lead time compared to standard care.

Abstract

Background Heart failure (HF) poses a global health challenge, with traditional management methods contributing to high readmission and mortality rates. This observational study evaluates the Heartfelt device for remote, autonomous monitoring of peripheral oedema, aiming to improve HF management. Methods Conducted from February 2020 to June 2022 across five UK NHS trusts, the FOOT Study ( NCT04072744 ) enrolled 31 patients, with 26 actively monitored. The study assessed the Heartfelt device’s predictive accuracy, data collection frequency, consistency versus traditional weighing (standard care), lead time for intervention and event prediction sensitivity. Results The Heartfelt device showed a notable lead time of 13 days for HF decompensation prediction, offering more consistent and frequent data than traditional methods. Among the monitored patients, six HF events were observed. Patient feedback was largely positive, with several participants choosing to keep the device poststudy. Conclusions Offering improvements over traditional methods, the Heartfelt device could enhance early HF decompensation detection through continuous oedema monitoring. This study highlights the transformative potential of remote monitoring in HF management, suggesting a need for further research to refine alert systems and assess long-term impacts. Trial registration number NCT04072744 .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dewhurst et al. (2026) studied this question. The Heartfelt remote monitoring device predicted heart failure decompensation with a 13-day lead time, providing more consistent and frequent data than traditional weighing methods.

synapsesocial.com/papers/69bb928c496e729e6297feebhttps://doi.org/10.1136/bmjinnov-2025-001394
Ask AI
Helpful
Bookmark
Share
View Full Paper